Full-Time

Associate Director

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$190k - $220k/yr

+ Equity component

San Carlos, CA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Inventory Management
GMP
Data Analysis

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • A PhD in Biochemistry, Immunology, Analytical Chemistry, Biological Sciences, or a related discipline with at least 7 years of relevant biopharmaceutical industry experience, or an M.S. in a related discipline with at least 10 years of relevant biopharmaceutical industry experience.
  • Significant hands-on experience with antibody reagent generation, screening, characterization, qualification, conjugation, labeling, lot bridging, stability assessment, and lifecycle management.
  • Experience managing immunoassay critical reagents, reference standards, assay controls, calibrators, and customized assay materials used in ligand-binding assays or vaccine analytical methods.
  • Experience planning, executing, and interpreting critical reagent and reference material stability studies, including protocol design, storage condition selection, timepoint testing, acceptance criteria, trend analysis, expiry or retest dating recommendations, and stability reporting.
  • Strong understanding of antibody-antigen interactions, assay reagent quality attributes, specificity, affinity, cross-reactivity, epitope behavior, matrix effects, reagent stability, and lot-to-lot comparability.
  • Experience developing and executing qualification strategies for critical reagents and reference materials, including acceptance criteria, bridging approaches, stability monitoring, lifecycle planning, and replenishment planning.
  • Hands-on experience with immunoassay platforms such as MSD, ELISA, electrochemiluminescence-based assays, multiplex assays, or other ligand-binding assay technologies.
  • Experience with customized immunoassay materials such as MSD plates, coated plates, labeled detection reagents, multiplex panels, assay kits, buffers, and other platform-specific critical components.
  • Experience supporting immunoassay method development, troubleshooting, optimization, method transfer, validation readiness, platform evaluation, or routine analytical testing.
  • Proven ability to troubleshoot reagent- or reference-material-related performance trends using structured, data-driven root-cause analysis approaches.
  • Demonstrated ability to oversee outsourced reagent generation, characterization, qualification, stability, custom assay material production, or testing activities.
  • Demonstrated ability to support daily laboratory operations, including reagent and reference material planning, study scheduling, inventory management, data review, documentation, and technical support.
  • Solid understanding of protein chemistry, polysaccharide chemistry, conjugation chemistry, antibody engineering or production, reagent conjugation, and biological sample matrix effects as applied to vaccine analytical development.
  • Strong organizational skills demonstrated through management of reagent inventories, reference material inventories, documentation systems, stability schedules, external deliverables, timelines, and cross-functional priorities.
  • Strong scientific judgment and the ability to make sound technical recommendations when working with incomplete, complex, or conflicting data.
  • Strong written and verbal communication skills for clearly communicating technical concepts, study results, risks, and recommendations to cross-functional stakeholders, external partners, and regulatory audiences.
  • Commitment to data integrity, documentation quality, scientific excellence, accountability, supply continuity, and continuous improvement.
Responsibilities
  • Contribute to establishing and growing the Immunoassay Development Capability within Global Analytical Development, with primary responsibility for immunoassay critical reagents, reference materials, customized assay materials, stability programs, and associated lifecycle management systems.
  • Engage daily in laboratory operations, including reagent planning, reference material planning, sample and material readiness, laboratory study coordination, inventory review, data review, documentation, and hands-on technical support.
  • Lead the generation, characterization, qualification, stability planning, lifecycle management, and inventory control of antibody reagents used in immunoassays.
  • Support antibody reagent generation strategies, including antigen design, immunization strategy, hybridoma or recombinant antibody generation, screening, clone selection, purification, conjugation, labeling, characterization, and long-term supply planning.
  • Develop and execute antibody characterization plans covering specificity, affinity, cross-reactivity, epitope behavior, lot-to-lot comparability, assay performance attributes, stability, and suitability for intended immunoassay use.
  • Lead the generation, characterization, qualification, bridging, stability planning, lifecycle management, and inventory control of reference materials, including reference standards, assay controls, calibrators, system suitability controls, bridging controls, and other assay performance control materials.
  • Design and execute critical reagent and reference material stability studies, including protocol development, storage condition assessment, timepoint planning, testing strategy, acceptance criteria, data interpretation, trend evaluation, expiry or retest dating recommendations, and stability report generation.
  • Lead the generation, characterization, qualification, and lifecycle management of customized immunoassay critical materials, including MSD plates, coated plates, Sulfo-TAG or other labeled detection reagents, bead-conjugated reagents, multiplex assay components, customized assay kits, buffers, blocking reagents, and other platform-specific critical materials.
  • Develop qualification and bridging strategies for new critical reagent lots, reference material lots, and customized assay material lots to support continuity of assay performance and data comparability.
  • Establish and maintain critical reagent and reference material inventory systems, including stock planning, usage forecasting, storage conditions, chain of custody, expiry or retest dating, reserve strategy, stability monitoring, documentation, and replenishment planning.
  • Partner with immunoassay development scientists to understand method-specific reagent requirements, assay design, critical material attributes, platform considerations, assay controls, and long-term control strategy needs.
  • Support immunoassay method development, optimization, troubleshooting, transfer, validation readiness, and routine analytical testing as needed.
  • Provide hands-on laboratory support for reagent characterization, reference material characterization, stability studies, assay qualification studies, bridging studies, comparability assessments, platform evaluation studies, and routine non-GMP or GMP-supporting analytical testing.
  • Lead or support investigations of reagent or reference material performance trends using structured, data-driven root-cause analysis approaches and clear experimental plans.
  • Oversee outsourced activities related to antibody generation, reagent manufacturing, reference material preparation, custom MSD plate production, customized kit generation, reagent characterization, stability studies, and critical material qualification.
  • Manage CRO, CDMO, contract testing laboratory, reagent vendor, and technology partner relationships, including technical scope definition, vendor selection support, statement of work input, protocol review, study monitoring, data review, scientific and technical problem-solving, timeline tracking, and deliverable acceptance.
  • Review and approve, as appropriate, external study plans, protocols, batch records, certificates of analysis, characterization reports, qualification reports, stability data, inventory records, and technical summaries related to critical reagents and reference materials.
  • Establish best practices for critical reagent documentation, including reagent history files, qualification packages, characterization reports, stability protocols and reports, inventory records, usage logs, certificates of analysis, lot-release records, bridging reports, and lifecycle management plans.
  • Support ASAT, QC, Quality, Regulatory, and external testing partners in method transfer, validation support, change control, deviation investigation, CAPA, reagent replenishment, reference material replenishment, and long-term assay lifecycle management.
  • Contribute to regulatory submissions, health authority responses, technical reports, method development reports, validation strategies, comparability packages, and BLA-supporting documentation related to critical reagents, reference materials, stability programs, and immunoassay control strategies.
  • Represent the CMC Immunoassay group in cross-functional project teams, technical reviews, vendor meetings, external collaborations, and governance forums as needed.
  • Mentor and provide technical guidance to laboratory scientists on reagent handling, reference material handling, characterization methods, stability study execution, qualification studies, troubleshooting, documentation, and good laboratory practices.
Desired Qualifications
  • Experience working with CROs, CDMOs, contract testing laboratories, reagent vendors, or external technology partners.
  • Experience working in or supporting GMP-regulated analytical environments, including familiarity with method qualification, validation, transfer, change control, deviations, investigations, CAPA, data integrity, critical reagent control, and lifecycle management.
  • Direct experience with conjugated vaccines, polysaccharide-protein conjugates, multivalent vaccines, or other complex biologics.
  • Experience supporting late-stage development, PPQ readiness, BLA preparation, commercial launch, or lifecycle management of vaccine or biologics programs.
  • Direct experience supporting critical reagents or reference materials used for GMP release and stability testing.
  • Experience with antibody discovery, hybridoma generation, recombinant antibody production, antibody purification, antibody conjugation, biotinylation, ruthenium labeling, fluorescent labeling, or bead conjugation.
  • Hands-on experience with MSD platforms, including custom plate coating, labeled detection reagents, and assay reagent qualification.
  • Hands-on experience with Luminex or other multiplex immunoassay platforms, including bead coupling, bead characterization, multiplex panel design, and lot bridging.
  • Experience managing outsourced antibody generation, reagent manufacturing, reference material preparation, customized assay kit production, stability studies, or critical reagent qualification with CROs, CDMOs, or reagent vendors.
  • Experience developing critical reagent control strategies, reagent history files, lifecycle management plans, stability protocols, bridging protocols, inventory control systems, and reagent replenishment strategies.
  • Experience contributing to health authority responses or regulatory submissions on analytical methods, critical reagents, reference standards, stability programs, potency assays, antigenicity assays, or immunoassay control strategies.
  • Experience helping build or scale analytical capabilities, critical reagent programs, or laboratory teams within a growing organization.
  • Experience with multivalent or highly complex vaccine programs.
  • Experience with automation, high-throughput reagent characterization workflows, electronic inventory systems, LIMS, ELN, and digital data analysis tools.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
  • The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
  • Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.

What critics are saying

  • VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
  • Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
  • Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.

What makes Vaxcyte unique

  • Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
  • OPUS trials were finalized with FDA alignment for a planned BLA submission.
  • Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-4%

2 year growth

-1%
Yahoo Finance
Sep 8th, 2026
Vaxcyte CFO surrenders shares for tax, company holds $2.5B cash against $605M loss

Vaxcyte's president and CFO Andrew Guggenhime disposed of 2,705 shares according to a recent SEC filing. The transaction involved shares surrendered to satisfy tax withholding obligations on vested restricted stock units, not a discretionary sale. Guggenhime retains approximately 164,000 shares valued at $10.12 million based on 2 September's market close. His holdings consist of 102,000 shares held directly and 61,850 shares held indirectly through ALG 2025 Grat Holdings LLC. The clinical-stage biotechnology company held $2.51 billion in cash and investments at the end of June. However, Vaxcyte reported a six-month net loss of $604.9 million, with second-quarter operating expenses reaching $302.8 million, up from $226.2 million the previous year. Vaxcyte's lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine, is currently in clinical trials. The company has a market capitalisation of $9 billion.

Yahoo Finance
Sep 8th, 2026
Vaxcyte CEO sells shares for tax purposes as biotech burns $284M ahead of pivotal vaccine trial

Vaxcyte CEO Grant Pickering disposed of 6,289 shares of common stock in a non-discretionary transaction to cover tax withholding obligations from vesting restricted stock units, according to an SEC filing. The shares were valued at approximately $385,000 based on a weighted average sale price of $61.20. The California-based clinical-stage biotechnology company is developing VAX-31, a 31-strain pneumococcal vaccine. Vaxcyte expects topline data in the fourth quarter from OPUS-1, its pivotal Phase 3 trial testing VAX-31 against Pfizer's Prevnar 20 and Merck's Capvaxive in approximately 4,000 adults aged 50 and older. The company burned $284.3 million in the June quarter alone, with research and development spending up 38% year-over-year to $267.9 million. Vaxcyte holds $2.5 billion in cash.

Yahoo Finance
Sep 6th, 2026
Vaxcyte posts $284M Q2 loss as three Phase 3 vaccine trials complete enrolment

Vaxcyte reported second-quarter results showing a net loss of $284.3 million, nearly double the $166.6 million loss from a year earlier. The clinical-stage vaccine maker has fully enrolled three Phase 3 trials for its lead pneumococcal candidate VAX-31, with 6,191 adults dosed across the studies. Research and development spending rose to $267.9 million from $194.2 million, driven by manufacturing preparation and trial costs. The company held $2.5 billion in cash and investments as of 30 June. The first major data readout from the OPUS-1 trial, comparing VAX-31 against Prevnar 20 and Capvaxive, is expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 will follow in the first half of 2027. Hedge fund ownership declined from 57 to 47 funds, whilst short interest stands at 10% of the float.

Yahoo Finance
Sep 3rd, 2026
Vaxcyte appoints ex-Pfizer vaccines CMO, narrows VAX-31 Phase 3 data timeline to October

Vaxcyte has appointed Luis Jodar and David McAvoy as chief medical officer and chief legal officer, respectively. The clinical-stage vaccine innovation company also narrowed its guidance for topline data from the VAX-31 adult Phase 3 OPUS-1 trial, now expecting results by the end of October 2026. Jodar joins from Pfizer, where he spent 17 years, most recently as senior vice president and chief medical officer for vaccines and infectious diseases. He led clinical development and regulatory strategy for programmes including Prevnar 13 and Prevnar 20. McAvoy previously served as chief legal officer at Teva. The appointments come as Vaxcyte prepares for its planned Biologics Licence Application submission and potential launch of VAX-31.

Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.